A randomized controlled trial on optimal administration frequency of continuous erythropoietin receptor activator in hemodialysis patients with renal anemia.

Randomized controlled trial of the effects with treatment efficiency and iron metabolism due to continuous erythropoietin receptor activator administration frequency in hemodialysis patients with renal anemia. - ACCERA study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031180030

Enrollment

120

Registered

2018-10-25

Start date

2019-02-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

renal anemia

Interventions

randomized

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Outpatients in maintenance hemodialysis with renal anemia (2) Patients over 20 years of age (3) Patients with a hemodialysis history of more than 12 weeks (4) Patients with a history of receiving erythropoiesis stimulating agents for more than 12 weeks (5) Patients who was obtained written informed consent regarding the participation of this study

Exclusion criteria

Exclusion criteria: (1)Heart failure above NYHA 3 degrees. (2)Poorly controlled high blood pressure (diastolic blood pressure before dialysis 110 mmHg or more). (3)Chemotherapy or radiotherapy for malignancy within 24 weeks. (4)Red blood cell transfusion within 12 weeks. (5)Major surgery within 12 weeks (thoracotomy, laparotomy etc.) (6)Patients who are pregnant. (7)Other patients judged inappropriate for the study by doctors.

Design outcomes

Primary

Measure	Time frame
The dose of epoetin beta pegol during 12 weeks of comparison period.	—

Secondary

Measure	Time frame
(1)hepcidin (2)ferittin and TSAT (3)Ret-Hb and Ret-He (4)Hb (5)ERI (6)the iron administration during comparison period. (7) Presence of discontinuation of protocol treatment due to red blood cell transfusion or ESA type change after starting of comparison period	—

Contacts

Public Contactyuki Kawai

Yokohama City University Hospital

ykawai2017@gmail.com+81-45-787-2800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026